Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2356 to 2370 of 7686 results

  1. Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]

    In development [GID-TA11058] Expected publication date: 21 May 2025

    Technology appraisal guidance
    In development

  2. Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317

    In development [GID-TA11340] Expected publication date: 21 May 2025

    Technology appraisal guidance
    In development

  3. Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines ID6356

    Awaiting development [GID-TA11416] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Ranibizumab port delivery system for treating diabetic macular oedema ID6137

    Awaiting development [GID-TA11065] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA963) [ID6426]

    Awaiting development [GID-TA11536] Expected publication date: 21 May 2025

    Technology appraisal guidance
    Awaiting development

  6. Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis TS ID 12050

      Status ...

    Technology appraisal guidance
    Topic selection

  7. Sotatercept for treating pulmonary arterial hypertension [ID6163]

    In development [GID-TA11103] Expected publication date: 15 October 2025

    Technology appraisal guidance
    In development

  8. Semaglutide for preventing major cardiovascular events in people with cardiovascular disease and living with overweight or obesity ID6441

    In development [GID-TA11544] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Human normal immunoglobulin for preventing infection in chronic lymphocytic leukaemia [ID6455]

      Status ...

    Technology appraisal guidance
    Topic selection

  10. Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]

    In development [GID-TA11504] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. KardiaMobile for detecting atrial fibrillation (MTG64)

    Evidence-based recommendations on KardiaMobile for detecting atrial fibrillation.

    Medical technologies guidance
    Last updated
    25 July 2023
    View recommendations

    Sections for MTG64

  12. GaitSmart rehabilitation exercise programme for gait and mobility issues (MTG78)

    Evidence-based recommendations on GaitSmart rehabilitation exercise programme for gait and mobility issues in adults.

    Medical technologies guidance
    Published
    3 April 2024
    View recommendations

    Sections for MTG78

  13. Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers (MTG40)

    Evidence-based recommendations on Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers.

    Medical technologies guidance
    Published
    10 January 2019
    View recommendations

    Sections for MTG40

  14. Curos for preventing infections when using needleless connectors (MTG44)

    Evidence-based recommendations on Curos for preventing infections when using needleless connectors.

    Medical technologies guidance
    Published
    9 May 2019
    View recommendations

    Sections for MTG44

  15. ENDURALIFE powered CRT-D devices for treating heart failure (MTG33)

    Evidence-based recommendations on ENDURALIFE-powered CRT-D devices for treating heart failure.

    Medical technologies guidance
    Last updated
    21 July 2021
    View recommendations

    Sections for MTG33